Delving deeper into stem cell treatment for ASD: In May 2020 the journal Molecular Autism published the following review of clinical trial data for Stem Cell treatment (MSC or SCT) for ASD: Cell Therapy Approaches to Autism: a Review of Clinical Trial Data. In his review of the literature, Dr Price brings to light many of the questions and challenges regarding SCT for ASD:
- Stem Cell therapy is being marketed shamelessly as a miracle autism cure. Families seeking answers for their children may be barraged by social media posts, texts, emails, and other ‘direct to consumer’ ads from questionable clinics that promise more than they can deliver and at great expense to families. SCT providers do not acknowledge the experimental nature of the therapy, and the lack of regulatory review of the treatment process.
- The global clinical research enterprise is important to provide safeguards to families of children with ASD with regard to Stem Cell Therapy and more broadly. While SCT clinical research is promising, it remains at a very early stage, with a very limited number of participants and without a strong track record of success. Many SCT clinical studies lack a clear therapeutic target and often have stopped in the middle for unspecified reasons.
- In terms of the best clinical research for SCT, a variety of protocols have been examined varying sources of stem cells (eg. donor cells, frozen umbilical cord blood cells from the child himself, fresh cells harvested from the child’s bone marrow etc) and methods of administration – so it is difficult to compare the data between the studies. Dr Price gives his suggestions for rectifying the situation with further study based on clear therapeutic targets.
Cell-El Ltd. is specifically focused on rectifying the state of SCT clinical research for ASD. We too believe that further study is warranted with well-researched treatment protocols and, of course, full regulatory approval. As far as a clear therapeutic target – Cell-El has designed a comprehensive pre-treatment diagnostic protocol focused on identifying a baseline understanding of what biologically we are treating when administering SCT – what the biological issues exist pre-treatment and how they possibly change – with objective biological measures. Cell-El Ltd. strives to bring to the ASD children and their families state of the art, science-backed data that to open up new, reliable, innovative treatment options.
Please join us in making a difference in the lives of children with ASD and their families! We are recruiting both participants who are typically developing as well as those dIagnosed with ASD. We are also looking for parents to help spread the word to others and thus enable this important tool to be integrated into Autism treatment as quickly as possible. And we want to hear from you about your concerns and challenges relating to ASD testing and related therapies. To contact us and learn more please click here.